The European Commission approves Alexion Pharmaceuticals’ (ALXN -0.5%) ULTOMIRIS (ravulizumab) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) with hemolysis with clinical symptoms indicative of high disease activity and for adult patients who are clinically stable after at least six months on SOLIRIS (eculizumab).
ULTOMIRIS, a long-acting C5 complement inhibitor, is administered once every eight weeks. SOLIRIS is dosed every two weeks after the lead-in period.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.